Silexion Therapeutics Corp披露,预计在未来数月内,将有更多来自以色列和德国的研究中心加入其Sil204 2/3期临床试验项目。这一举措旨在进一步扩大试验的地域覆盖范围,并推动候选药物的临床开发进程。
Silexion Therapeutics Corp披露,预计在未来数月内,将有更多来自以色列和德国的研究中心加入其Sil204 2/3期临床试验项目。这一举措旨在进一步扩大试验的地域覆盖范围,并推动候选药物的临床开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.